liraglutide semaglutide tirzepatide vs. Other GLP-1 Receptor Agonists Real-World Effectiveness and Safety of

For most patients they are temporary clinical trial data shows that only a small percentage of patients stopped treatment because of them

Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes

Furihata K, Mimura H, Urva S, et al

Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a dual GIP and GLP-1 receptor agonist that can affect energy levels through reduced appetite, slower gastric emptying, and caloric restriction

Expertly designed formulas Created with specialist knowledge in weight wellness to provide effective support

Absorption may be slower or less complete